% | $
Quotes you view appear here for quick access.

Shire plc Message Board

  • larry_boe larry_boe Oct 9, 2006 4:01 PM Flag

    Wow! Before Approval AMRI Inks Deal

    With NRPH, To Make Active Ingredient For Compound NRP104! Back In July!!!!!!!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • AMRI worth more imo. Taken from that pr/ AMRI Announces Long-Term Manufacturing Agreement with New River Pharmaceuticals
      Monday July 24, 9:41 am ET

      ALBANY, N.Y.--(BUSINESS WIRE)--July 24, 2006--Albany Molecular Research, Inc. (Nasdaq: AMRI - News) today announced a multi-year drug substance manufacturing agreement with New River Pharmaceuticals Inc. (Nasdaq: NRPH - News). Financial terms were not disclosed.

      Under the agreement, AMRI will manufacture the active pharmaceutical ingredient in New River's compound, NRP104, a new treatment for attention deficit hyperactivity disorder (ADHD) that is currently under review with the U.S. Food and Drug Administration. AMRI participated with New River in the development of the chemical process to manufacture NRP104.

      "AMRI is delighted to continue its relationship with New River Pharmaceuticals," said AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D. "We are well positioned to manufacture this compound based on our long history of manufacturing, as well as our strength in chemical development. Our expertise and specialized capabilities in the area of active ingredient manufacturing provide a unique and value-added capability to AMRI customers."

      Krish Krishnan, New River's Chief Financial Officer and Chief Operating Officer, commented, "We are confident that AMRI is a solid choice for manufacture. AMRI has the current capability of delivering a quality product in a timely manner, leading us to conclude that it is the best candidate for manufacturing NRP104 for an expected product launch in the first quarter of 2007."

      John Quirk, 646-536-7029
      Zack Kubow, 646-536-7020

      ----------------------------------------------------- ---------------------------
      Source: Albany Molecular Research, Inc.